- Home
- TOPS vs CURX Comparison
TOPS vs CURX Comparison
Compare TOPS & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOPS | CURX |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 14.5M |
| IPO Year | 2004 | 2025 |
Fundamental Metrics
Financial Performance| Metric | TOPS | CURX |
|---|---|---|
| Price | $3.03 | $0.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 358.5K | 329.5K |
| Earning Date | 03-19-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.05 | $0.26 |
| 52 Week High | $11.47 | $9.18 |
Technical Indicators
Market Signals| Indicator | TOPS | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 32.95 | 63.66 |
| Support Level | N/A | $0.37 |
| Resistance Level | $6.18 | $0.56 |
| Average True Range (ATR) | 0.29 | 0.05 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 5.55 | 74.99 |
Price Performance
Historical ComparisonAbout TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.